Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells
- Katie
- 0
Soluble Membrane Assault Advanced: Biochemistry and Immunobiology
The soluble membrane assault advanced (sMAC, a.okay.a., sC5b-9 or TCC) is generated on activation of complement and accommodates the complement proteins C5b, C6, C7, C8, C9 along with the regulatory proteins clusterin and/or vitronectin.
sMAC is a member of the MACPF/cholesterol-dependent-cytolysin superfamily of pore-forming molecules that insert into lipid bilayers and disrupt mobile integrity and performance. sMAC is a singular complement activation macromolecule as it’s comprised of a number of totally different subunits.
Thus far no complement-mediated perform has been recognized for sMAC. sMAC is current in blood and different physique fluids underneath homeostatic circumstances and there’s considerable proof documenting modifications in sMAC ranges throughout an infection, autoimmune illness and trauma.
Regardless of many years of scientific curiosity in sMAC, the mechanisms regulating its formation in wholesome people and its organic capabilities in each well being and illness stay poorly understood.
Right here, we assessment the structural variations between sMAC and its membrane counterpart, MAC, and look at sMAC immunobiology with respect to its presence in physique fluids in well being and illness. Lastly, we focus on the diagnostic potential of sMAC for diagnostic and prognostic functions and potential utility as a companion diagnostic.
AAV5-GFP Control Virus |
|||
AAV-305 | Cell Biolabs | 50 ?L | EUR 1221.6 |
Description: GFP control virus of AAV serotype 5. |
AAV6-GFP Control Virus |
|||
AAV-306 | Cell Biolabs | 50 ?L | EUR 1221.6 |
Description: GFP control virus of AAV serotype 6. |
AAV2 Null Control Virus |
|||
AAV-352 | Cell Biolabs | 50 ?L | EUR 1221.6 |
Description: Null (empty) control virus of AAV serotype 2. |
AAV3 Null Control Virus |
|||
AAV-353 | Cell Biolabs | 50 ?L | EUR 1221.6 |
Description: Null (empty) control virus of AAV serotype 3. |
AAV4 Null Control Virus |
|||
AAV-354 | Cell Biolabs | 50 ?L | EUR 1221.6 |
Description: Null (empty) control virus of AAV serotype 4. |
AAV5 Null Control Virus |
|||
AAV-355 | Cell Biolabs | 50 ?L | EUR 1221.6 |
Description: Null (empty) control virus of AAV serotype 5. |
AAV6 Null Control Virus |
|||
AAV-356 | Cell Biolabs | 50 ?L | EUR 1221.6 |
Description: Null (empty) control virus of AAV serotype 6. |
AAV2-Cre Control Virus |
|||
AAV-310 | Cell Biolabs | 50 ?L | EUR 1221.6 |
Description: Cre control virus of AAV serotype 2. |
AAV3-Cre Control Virus |
|||
AAV-313 | Cell Biolabs | 50 ?L | EUR 1221.6 |
Description: Cre control virus of AAV serotype 3. |
AAV4-Cre Control Virus |
|||
AAV-314 | Cell Biolabs | 50 ?L | EUR 1221.6 |
Description: Cre control virus of AAV serotype 4. |
AAV5-Cre Control Virus |
|||
AAV-315 | Cell Biolabs | 50 ?L | EUR 1221.6 |
Description: Cre control virus of AAV serotype 5. |
AAV6-Cre Control Virus |
|||
AAV-316 | Cell Biolabs | 50 ?L | EUR 1221.6 |
Description: Cre control virus of AAV serotype 6. |
AAV2-Luc Control Virus |
|||
AAV-320 | Cell Biolabs | 50 ?L | EUR 1221.6 |
Description: Luciferase control virus of AAV serotype 2. |
AAV3-Luc Control Virus |
|||
AAV-323 | Cell Biolabs | 50 ?L | EUR 1221.6 |
Description: Luciferase control virus of AAV serotype 3. |
AAV4-Luc Control Virus |
|||
AAV-324 | Cell Biolabs | 50 ?L | EUR 1221.6 |
Description: Luciferase control virus of AAV serotype 4. |
AAV5-Luc Control Virus |
|||
AAV-325 | Cell Biolabs | 50 ?L | EUR 1221.6 |
Description: Luciferase control virus of AAV serotype 5. |
AAV6-Luc Control Virus |
|||
AAV-326 | Cell Biolabs | 50 ?L | EUR 1221.6 |
Description: Luciferase control virus of AAV serotype 6. |
AAV2-LacZ Control Virus |
|||
AAV-342 | Cell Biolabs | 50 ?L | EUR 1221.6 |
Description: LacZ control virus of AAV serotype 2. |
AAV3-LacZ Control Virus |
|||
AAV-343 | Cell Biolabs | 50 ?L | EUR 1221.6 |
Description: LacZ control virus of AAV serotype 3. |
AAV4-LacZ Control Virus |
|||
AAV-344 | Cell Biolabs | 50 ?L | EUR 1221.6 |
Description: LacZ control virus of AAV serotype 4. |
AAV5-LacZ Control Virus |
|||
AAV-345 | Cell Biolabs | 50 ?L | EUR 1221.6 |
Description: LacZ control virus of AAV serotype 5. |
AAV6-LacZ Control Virus |
|||
AAV-346 | Cell Biolabs | 50 ?L | EUR 1221.6 |
Description: LacZ control virus of AAV serotype 6. |
saCas9 Nuclease AAV Virus (AAV1) |
|||
K208 | ABM | 2 x 250 µl, 1 x 10^9 GC/ml, Titer: 1 x 10^9 GC/ml | EUR 375 |
Description: This AAV vector expresses the Cas9 orthologue from Staphylococcus Aureus (saCas9). saCas9 is ~1 kb shorter than spCas9, allowing it to be efficiently packaged in AAV Virus. Furthermore, the saCas9 enzyme recognizes a longer PAM sequence than spCas9, and thus has greater editing specificity.AAV has low immunogenicity and broad host range, making it an ideal choice for both in vivo and in vitro applications. Use this saCas9-expressing AAV virus with a target-specific saCas9-compatible sgRNA for highly specific and efficient genome editing. |
scAAV1-GFP Control Virus |
|||
AAV-331 | Cell Biolabs | 50 ?L | EUR 1221.6 |
Description: Self-complementary GFP control virus of AAV serotype 1. |
scAAV2-GFP Control Virus |
|||
AAV-332 | Cell Biolabs | 50 ?L | EUR 1221.6 |
Description: Self-complementary GFP control virus of AAV serotype 2. |
scAAV3-GFP Control Virus |
|||
AAV-333 | Cell Biolabs | 50 ?L | EUR 1221.6 |
Description: Self-complementary GFP control virus of AAV serotype 3. |
scAAV4-GFP Control Virus |
|||
AAV-334 | Cell Biolabs | 50 ?L | EUR 1221.6 |
Description: Self-complementary GFP control virus of AAV serotype 4. |
scAAV5-GFP Control Virus |
|||
AAV-335 | Cell Biolabs | 50 ?L | EUR 1221.6 |
Description: Self-complementary GFP control virus of AAV serotype 5. |
scAAV6-GFP Control Virus |
|||
AAV-336 | Cell Biolabs | 50 ?L | EUR 1221.6 |
Description: Self-complementary GFP control virus of AAV serotype 6. |
Lenti-III-UBC-GFP Control Virus |
|||
LV027 | ABM | 4 x 500 ul | EUR 195 |
Lenti-III-PGK-GFP Control Virus |
|||
LV028 | ABM | 4 x 500 ul | EUR 195 |
Lenti-III-EF1alpha-GFP Control Virus |
|||
LV046 | ABM | 4 x 500 ul | EUR 195 |
pCDH-Cuo-RFP-T2A-GFP (positive control virus) |
|||
QM350VA-1 | SBI | >1 x 10^6 IFUs | EUR 573 |
HSV-1 Virus Control Stock |
|||
20-4810020 | Quidel | Single Use, 400 µL, shipped frozen | Ask for price |
Description: Genetically Engineered BHK Cells |
HSV-2 Virus Control Stock |
|||
20-4820020 | Quidel | Single Use, 400 µL, shipped frozen | Ask for price |
Description: Genetically Engineered BHK Cells |
Zika Virus NS1 Control Antigen |
|||
BA149R01 | Genovis AB | 1 mg | EUR 947 |
Measles Virus IgG Control Serum |
|||
C102G | Genovis AB | 3 mL | EUR 105 |
Measles Virus IgM Control Serum |
|||
C102M | Genovis AB | 3 mL | EUR 105 |
Rubella Virus IgG Control Serum |
|||
C129G | Genovis AB | 3 mL | EUR 105 |
Rubella Virus IgM Control Serum |
|||
C129M | Genovis AB | 3 mL | EUR 105 |
Lenti-III-PGK-Luc Control Virus |
|||
LV088 | ABM | 4 x 500 ul | EUR 195 |
pRedTK-CMV Virus [positive control] |
|||
SR10052VA-1 | SBI | >2 x 10^6 IFUs | EUR 625 |
pRedZeo-CMV Virus [positive control] |
|||
SR10046VA-1 | SBI | >2 x 10^6 IFUs | EUR 625 |
pGreenZeo-CMV Virus [positive control] |
|||
SR501VA-1 | SBI | >2 x 10^6 IFUs | EUR 608 |
Zika Virus Human IgA Assay Control |
|||
BC149A | Genovis AB | 1 mL | EUR 105 |
Zika Virus Human IgG Assay Control |
|||
BC149G | Genovis AB | 1 mL | EUR 105 |
Zika Virus Human IgM Assay Control |
|||
BC149M | Genovis AB | 1 mL | EUR 105 |
pGreenZeo-mCMV Virus [negative control] |
|||
SR500VA-1 | SBI | >2 x 10^6 IFUs | EUR 608 |
Dengue Virus Human IgG Assay Control |
|||
BC114G | Genovis AB | 1 mL | EUR 105 |
Dengue Virus Human IgM Assay Control |
|||
BC114M | Genovis AB | 1 mL | EUR 105 |
Influenza A Virus IgA Control Serum |
|||
C1231A | Genovis AB | 3 mL | EUR 105 |
Influenza A Virus IgG Control Serum |
|||
C1231G | Genovis AB | 3 mL | EUR 105 |
Influenza A Virus IgM Control Serum |
|||
C1231M | Genovis AB | 3 mL | EUR 105 |
Influenza B Virus IgA Control Serum |
|||
C1232A | Genovis AB | 3 mL | EUR 105 |
Influenza B Virus IgG Control Serum |
|||
C1232G | Genovis AB | 3 mL | EUR 105 |
Influenza B Virus IgM Control Serum |
|||
C1232M | Genovis AB | 3 mL | EUR 105 |
Mumps Virus Nucleoprotein Control Antigen |
|||
BA103R01 | Genovis AB | 1 mg | EUR 1016 |
Measles Virus Nucleoprotein Control Antigen |
|||
BA102R01 | Genovis AB | 1 mg | EUR 1016 |
Mumps/Parotitis Virus IgG Control Serum |
|||
C103G | Genovis AB | 3 mL | EUR 105 |
Mumps/Parotitis Virus IgM Control Serum |
|||
C103M | Genovis AB | 3 mL | EUR 105 |
EZ‐Seneca Valley Virus A Control Set |
|||
TC-9080-096 | Tetracore | each | EUR 90 |
Chikungunya Virus Human IgG Assay Control |
|||
BC148G | Genovis AB | 1 mL | EUR 105 |
Chikungunya Virus Human IgM Assay Control |
|||
BC148M | Genovis AB | 1 mL | EUR 105 |
Adeno-Associated Virus 1 / AAV1 (intact particle) mouse monoclonal antibody, clone ADK1a, Purified |
|||
BM5093 | Origene Technologies GmbH | 50 µg | Ask for price |
Varicella-Zoster Virus IgA Control Serum |
|||
C104A | Genovis AB | 3 mL | EUR 105 |
Varicella-Zoster Virus IgG Control Serum |
|||
C104G | Genovis AB | 3 mL | EUR 105 |
Varicella-Zoster Virus IgM Control Serum |
|||
C104M | Genovis AB | 3 mL | EUR 105 |
West Nile Virus Human IgG Assay Control |
|||
BC141G | Genovis AB | 1 mL | EUR 105 |
West Nile Virus Human IgM Assay Control |
|||
BC141M | Genovis AB | 1 mL | EUR 105 |
Virus-Like Particles (VLPs) isotype control |
|||
CSB-MP3838 | Cusabio | 11453 mg | Ask for price |
Parainfluenza Virus Human IgA Assay Control |
|||
BC126A | Genovis AB | 1 mL | EUR 105 |
Parainfluenza Virus Human IgG Assay Control |
|||
BC126G | Genovis AB | 1 mL | EUR 105 |
Herpes Simplex Virus 1 IgM Control Serum |
|||
C1051M | Genovis AB | 3 mL | EUR 105 |
Herpes Simples Virus 2 IgM Control Serum |
|||
C1052M | Genovis AB | 3 mL | EUR 105 |
Epstein-Barr Virus EA IgG Control Serum |
|||
C1363G | Genovis AB | 3 mL | EUR 105 |
Respiratory Syncytial Virus IgA Control Serum |
|||
C113A | Genovis AB | 3 mL | EUR 105 |
Respiratory Syncytial Virus IgG Control Serum |
|||
C113G | Genovis AB | 3 mL | EUR 105 |
Epstein-Barr Virus VCA IgG Control Serum |
|||
C1361G | Genovis AB | 3 mL | EUR 105 |
Epstein-Barr Virus VCA IgM Control Serum |
|||
C1361M | Genovis AB | 3 mL | EUR 105 |
Dengue Virus superior Human IgM Assay Control |
|||
BC1141M | Genovis AB | 1 mL | EUR 105 |
Influenza A virus HA Control/blocking peptide |
|||
AB-23091-P | Alpha Diagnostics | 100ug | EUR 196.8 |
Herpes Simplex Virus 1 gP IgG Control Serum |
|||
C1051G | Genovis AB | 3 mL | EUR 105 |
Herpes Simplex Virus 2 gP IgG Control Serum |
|||
C1052G | Genovis AB | 3 mL | EUR 105 |
Herpes Simplex Virus 1+2 IgA Control Serum |
|||
C105A | Genovis AB | 3 mL | EUR 105 |
Herpes Simplex Virus 1+2 IgG Control Serum |
|||
C105G | Genovis AB | 3 mL | EUR 105 |
Herpes Simplex Virus 1+2 IgM Control Serum |
|||
C105M | Genovis AB | 3 mL | EUR 105 |
Adeno-Associated Virus 1 / AAV1 (intact particle) mouse monoclonal antibody, clone ADK1a, Biotin, Purified |
|||
BM5093B | Origene Technologies GmbH | 750 µl | Ask for price |
Virus-Like Particle (VLP) Protein Isotype Control |
|||
VLP-N5213 | ACROBIOSYSTEMS | 30ug | EUR 428 |
Description: VLP isotype control (VLP-N5213) is expressed from human 293 cells (HEK293). |
Tick-Borne Encephalitis Virus IgG Control Serum |
|||
C112G | Genovis AB | 3 mL | EUR 105 |
Tick-Borne Encephalitis Virus IgM Control Serum |
|||
C112M | Genovis AB | 3 mL | EUR 105 |
Epstein-Barr Virus EBNA-1 IgG Control Serum |
|||
C1362G | Genovis AB | 3 mL | EUR 105 |
Vaccinia virus Complement control protein C3 (VACWR025) |
|||
1-CSB-YP302389VAI | Cusabio |
|
|
Description: Recombinant Vaccinia virus Complement control protein C3(VACWR025) expressed in Yeast |
AAV1 SaCas9 |
|||
78479 | BPS Bioscience | 50 µl x 2 | EUR 545 |
Description: Adeno-Associated Virus Serotype 1 (AAV1) exhibits high homology with other AAV serotypes. AAV1 efficiently transduces muscle tissue, as determined by a region of the capsid protein VP1 (amino acids 350 to 430) which functions as a major determinant of tissue tropism._x000D_Cas9 is an endonuclease enzyme that introduces a double stranded break into the DNA when recruited to a specific DNA sequence by the sgRNA (single guide RNA). This double stranded break is repaired in mammalian cells either through Non-Homologous End Joining or Homologous Recombination. Non-Homologous End Joining often results in the deletion or insertion of several base pairs at the cut site, which, when resulting in a frameshift, causes the functional inactivation of the gene._x000D_SaCas9 (Staphylococcus aureus CRISPR-associated protein 9) has demonstrated high cutting efficiency in mammalian cells, and its smaller size makes it ideal for packaging into AAV. SaCas9 recognizes a longer protospacer adjacent motif (PAM) site, 5'-NNGRRT-3', than the more traditional SpCas9 (Streptococcus pyogenes CRISPR-associated protein 9). These AAV particles constitutively express SaCas9 under the control of a CMV promoter. |
pGreenFire 2.0-CMV positive control virus (pGF2-CMV-rFluc-T2A-GFP-mPGK-Puro) |
|||
TR410VA-P | SBI | >2 x 10^6 IFUs | EUR 632 |
AAV1 ZsGreen |
|||
78443 | BPS Bioscience | 50 µl x 2 | EUR 545 |
Description: Adeno-Associated Virus Serotype 1 (AAV1) exhibits high homology with other AAV serotypes. AAV1 efficiently transduces muscle tissue, as determined by a region of the capsid protein VP1 (amino acids 350 to 430) which functions as a major determinant of tissue tropism._x000D_These AAV1 particles constitutively express ZsGreen under a CMV promoter. ZsGreen is a human codon-optimized variant of the green fluorescent protein isolated from reef coral (Zoanthus sp). It has been engineered for higher expression in mammalian cells and is up to four times brighter than enhanced GFP (eGFP). ZsGreen expression and AAV1 transduction efficiency can easily be verified and optimized by fluorescence microscopy or flow cytometry. ZsGreen has an excitation wavelength of 493 nm and an emission wavelength of 505 nm. |
pGreenPuro Scramble Hairpin Control - Virus (for shRNAs and miRZips) |
|||
MZIP000-VA-1 | SBI | >1 x 10^6 IFUs | EUR 652 |
AAV1 antibody |
|||
10R-2473 | Fitzgerald | 5 mL | EUR 550.8 |
Description: Mouse monoclonal AAV1 antibody |
pGreenFire 2.0-mCMV negative control virus (pGF2-mCMV-rFluc-T2A-GFP-mPGK-Puro) |
|||
TR411VA-P | SBI | >2 x 10^6 IFUs | EUR 632 |
AAV1 Luciferase |
|||
78452 | BPS Bioscience | 50 µl x 2 | EUR 545 |
Description: Adeno-Associated Virus Serotype 1 (AAV1) exhibits high homology with other AAV serotypes. AAV1 efficiently transduces muscle tissue, as determined by a region of the capsid protein VP1 (amino acids 350 to 430) which functions as a major determinant of tissue tropism._x000D_These AAV particles constitutively express the firefly (Photinus pyralis) luciferase under the control of a CMV promoter. |
Baboon Anti-Rabies Virus IgG antiserum negative control |
|||
600-070-03N | Alpha Diagnostics | 1 ml | EUR 196.8 |
Baboon Anti-Rabies Virus IgG antiserum positive control |
|||
600-070-04P | Alpha Diagnostics | 1 ml | EUR 270 |
Camelpox virus H3L/p35 protein control for western blot |
|||
CPOX11-C | Alpha Diagnostics | 100 ul | EUR 343.2 |
Zika Virus prM Protein (African) control for Western blot |
|||
ZPRM11-C | Alpha Diagnostics | 100 ul | EUR 343.2 |
Recombinant Polyoma Virus (KV, Pneumotropic virus) Capsid Protein 1 (VP1) control for Western blot |
|||
KVP14-C | Alpha Diagnostics | 100 ul | EUR 343.2 |
NATtrol BK Virus External Run Control, Low (6 X 1 mL) |
|||
NATBK-ERCL | Zeptometrix | 6 X 1 mL | EUR 360 |
Mayaro virus (MAYV) 6K Protein control for Western Blotting |
|||
MAYV51-C | Alpha Diagnostics | 100 ug | EUR 343.2 |
Mayaro virus (MAYV) E3 protein control for Western Blotting |
|||
MAYV61-C | Alpha Diagnostics | 100 ul | EUR 343.2 |
Recombinant yellow fever virus Env protein [His] (WB control) |
|||
DAG-832 | Creative Diagnostics | 100 uL | EUR 729.75 |
Description: Recombinant |
Simian virus 5 (starin W3) P/V Control/blocking peptide |
|||
AB-23077-P | Alpha Diagnostics | 100ug | EUR 196.8 |
Fluorescent Virus-Like Particle (VLP) Protein Isotype Control |
|||
VLP-NF2P4 | ACROBIOSYSTEMS | 30ug | EUR 428 |
Description: Fluorescent VLP isotype control (VLP-NF2P4) is expressed from human 293 cells (HEK293). |
NATtrol Zika Virus, External Run Control, Low (6 x 1 mL) |
|||
NATZIKV-ERCL | Zeptometrix | 6 x 1 mL | EUR 350 |
Mayaro virus (MAYV) nsP1 protein control for Western Blotting |
|||
MAYV41-C | Alpha Diagnostics | 100 ul | EUR 343.2 |
Purified Nipah virus Glycoprotein control for Western Blotting |
|||
NIV11-C | Alpha Diagnostics | 100 ul | EUR 343.2 |
NATtrol BK Virus External Run Control, Medium (6 X 1 mL) |
|||
NATBK-ERCM | Zeptometrix | 6 X 1 mL | EUR 438 |
Purified Nipah virus Nucleoprotein control for Western Blotting |
|||
NIV21-C | Alpha Diagnostics | 100 ul | EUR 270 |
Human Anti-Mumps Virus (parotitis) IgG negative control serum |
|||
520-100-01N | Alpha Diagnostics | 1 ml | EUR 196.8 |
Human Anti-Mumps Virus (parotitis) IgG positive control serum |
|||
520-100-02P | Alpha Diagnostics | 1 ml | EUR 270 |
Mouse Anti-Mumps Virus (parotitis) IgG negative control serum |
|||
520-130-05N | Alpha Diagnostics | 1 ml | EUR 196.8 |
Mouse Anti-Mumps Virus (parotitis) IgG positive control serum |
|||
520-130-06P | Alpha Diagnostics | 1 ml | EUR 270 |
Mayaro virus (MAYV) Capsid Protein control for Western Blotting |
|||
MAYV31-C | Alpha Diagnostics | 100 ul | EUR 343.2 |
NATtrol Zika Virus, External Run Control, Medium (6 x 1 mL) |
|||
NATZIKV-ERCM | Zeptometrix | 6 x 1 mL | EUR 425 |
Recombinant Vaccinia virus Complement control protein C3 (VACWR025) |
|||
CSB-YP302389VAI | Cusabio | 6104 mg | Ask for price |
Recombinant Vaccinia virus Complement control protein C3(VACWR025) |
|||
AP74192 | SAB | 1mg | EUR 3389 |
Monkey Anti-Mumps Virus (parotitis) IgG negative control serum |
|||
520-160-03N | Alpha Diagnostics | 1 ml | EUR 196.8 |
Monkey Anti-Mumps Virus (parotitis) IgG positive control serum |
|||
520-160-04P | Alpha Diagnostics | 1 ml | EUR 270 |
Cynos Monkey Anti-Rabies Virus IgG antiserum positive control |
|||
600-070-06P | Alpha Diagnostics | 1 ml | EUR 270 |
Bovine Lumpy skin disease virus (LSDV) control for western blot |
|||
LSDV11-C | Alpha Diagnostics | 100 ul | EUR 343.2 |
Rabies Virus Glycoprotein (~58 kda, RVG) control for western blot |
|||
RBVGP11-C | Alpha Diagnostics | 100 ul | EUR 343.2 |
Rhesus Monkey Anti-Rabies Virus IgG antiserum negative control |
|||
600-070-01N | Alpha Diagnostics | 1 ml | EUR 196.8 |
Rhesus Monkey Anti-Rabies Virus IgG antiserum positive control |
|||
600-070-02P | Alpha Diagnostics | 1 ml | EUR 270 |
Camel Anti-Camelpox virus H3L/p35 IgG negative control serum |
|||
AE-311170-01N | Alpha Diagnostics | 1 ml | EUR 196.8 |
Camel Anti-Camelpox virus H3L/p35 IgG positive control serum |
|||
AE-311170-02P | Alpha Diagnostics | 1 ml | EUR 270 |
OPEF01337-1ML - Epstein-Barr Virus (EBV) Negative Control Extract |
|||
OPEF01337-1ML | Aviva Systems Biology | 1ml | EUR 174 |
OPEF01337-25ML - Epstein-Barr Virus (EBV) Negative Control Extract |
|||
OPEF01337-25ML | Aviva Systems Biology | 25ml | EUR 2901 |
Control/Blocking peptide for Tobacco Mosaic Virus Movement Protein |
|||
TMVMP11-P | Alpha Diagnostics | 100 ug | EUR 196.8 |
Varicella Zoster Virus (VZV) Envelope Glycoprotein E Control Antigen |
|||
BA104R02 | Genovis AB | 1 mg | EUR 953 |
saCas9 Nuclease AAV Virus (AAV11) |
|||
K218 | ABM | 2 x 250 µl, 1 x 10^9 GC/ml, Titer: 1 x 10^9 GC/ml | EUR 375 |
Description: This AAV vector expresses the Cas9 orthologue from Staphylococcus Aureus (saCas9). saCas9 is ~1 kb shorter than spCas9, allowing it to be efficiently packaged in AAV Virus. Furthermore, the saCas9 enzyme recognizes a longer PAM sequence than spCas9, and thus has greater editing specificity.AAV has low immunogenicity and broad host range, making it an ideal choice for both in vivo and in vitro applications. Use this saCas9-expressing AAV virus with a target-specific saCas9-compatible sgRNA for highly specific and efficient genome editing. |
saCas9 Nuclease AAV Virus (AAV10) |
|||
K217 | ABM | 2 x 250 µl, 1 x 10^9 GC/ml, Titer: 1 x 10^9 GC/ml | EUR 375 |
Description: This AAV vector expresses the Cas9 orthologue from Staphylococcus Aureus (saCas9). saCas9 is ~1 kb shorter than spCas9, allowing it to be efficiently packaged in AAV Virus. Furthermore, the saCas9 enzyme recognizes a longer PAM sequence than spCas9, and thus has greater editing specificity.AAV has low immunogenicity and broad host range, making it an ideal choice for both in vivo and in vitro applications. Use this saCas9-expressing AAV virus with a target-specific saCas9-compatible sgRNA for highly specific and efficient genome editing. |
AAV1 ELISA Kit |
|||
55R-PROPRAAV1 | Fitzgerald | 96 tests | EUR 1153 |
Description: ELISA kit for detection of AAV1 in the research laboratory |
Monkey (Cynomolgous) Anti-Rabies Virus IgG antiserum negative control |
|||
600-070-05N | Alpha Diagnostics | 1 ml | EUR 196.8 |
Influenza A virus (H5N1) matrix protein 2 Control/blocking peptide |
|||
M2E15-P | Alpha Diagnostics | 100 ug | EUR 196.8 |
Influenza A virus (H1N1) matrix protein 2 Control/blocking peptide |
|||
M2E16-P | Alpha Diagnostics | 100 ug | EUR 196.8 |
Influenza A virus (H9N2) matrix protein 2 Control/blocking peptide |
|||
M2E17-P | Alpha Diagnostics | 100 ug | EUR 196.8 |
Bovine Anti-Lumpy skin disease virus (LSDV) negative control serum |
|||
RV-500700-01N | Alpha Diagnostics | 1 ml | EUR 196.8 |
Bovine Anti-Lumpy skin disease virus (LSDV) positive control serum |
|||
RV-500700-02P | Alpha Diagnostics | 1 ml | EUR 270 |
Respiratory Syncytial Virus (RSV) Rapid Test Control Pack (2 X 1.5mL) |
|||
KZMC034 | Zeptometrix | RSV Rapid Test Control Pack | EUR 59 |
NATtrol Zika Virus (PRVABC59), External Run Control, Medium (6 x 1.0mL) |
|||
NATZIKV(PRV)-ERCM | Zeptometrix | 6 x 1.0mL | EUR 425 |
AAV1 Empty Capsids |
|||
DAGC255L | Creative Diagnostics | 10 µL, 30 µL | Ask for price |
Description: Recombinant |
NATtrol Zika Virus (PRVABC59), External Run Control, Low (6 x 1.0 mL) |
|||
NATZIKV(PRV)-ERCL | Zeptometrix | 6 x 1.0 mL | EUR 350 |
Bovine Viral Diarrhea Virus 2 E2 (BVDV2E2) IgG negative control serum |
|||
RV-500100-03N | Alpha Diagnostics | 1 ml | EUR 196.8 |
saCas9 Nuclease AAV Virus (AAV4) |
|||
K211 | ABM | 2 x 250 µl, 1 x 10^9 GC/ml, Titer: 1 x 10^9 GC/ml | EUR 375 |
Description: This AAV vector expresses the Cas9 orthologue from Staphylococcus Aureus (saCas9). saCas9 is ~1 kb shorter than spCas9, allowing it to be efficiently packaged in AAV Virus. Furthermore, the saCas9 enzyme recognizes a longer PAM sequence than spCas9, and thus has greater editing specificity.AAV has low immunogenicity and broad host range, making it an ideal choice for both in vivo and in vitro applications. Use this saCas9-expressing AAV virus with a target-specific saCas9-compatible sgRNA for highly specific and efficient genome editing. |
saCas9 Nuclease AAV Virus (AAV5) |
|||
K212 | ABM | 2 x 250 µl, 1 x 10^9 GC/ml, Titer: 1 x 10^9 GC/ml | EUR 375 |
Description: This AAV vector expresses the Cas9 orthologue from Staphylococcus Aureus (saCas9). saCas9 is ~1 kb shorter than spCas9, allowing it to be efficiently packaged in AAV Virus. Furthermore, the saCas9 enzyme recognizes a longer PAM sequence than spCas9, and thus has greater editing specificity.AAV has low immunogenicity and broad host range, making it an ideal choice for both in vivo and in vitro applications. Use this saCas9-expressing AAV virus with a target-specific saCas9-compatible sgRNA for highly specific and efficient genome editing. |
saCas9 Nuclease AAV Virus (AAV2) |
|||
K209 | ABM | 2 x 250 µl, 1 x 10^9 GC/ml, Titer: 1 x 10^9 GC/ml | EUR 375 |
Description: This AAV vector expresses the Cas9 orthologue from Staphylococcus Aureus (saCas9). saCas9 is ~1 kb shorter than spCas9, allowing it to be efficiently packaged in AAV Virus. Furthermore, the saCas9 enzyme recognizes a longer PAM sequence than spCas9, and thus has greater editing specificity.AAV has low immunogenicity and broad host range, making it an ideal choice for both in vivo and in vitro applications. Use this saCas9-expressing AAV virus with a target-specific saCas9-compatible sgRNA for highly specific and efficient genome editing. |
saCas9 Nuclease AAV Virus (AAV3) |
|||
K210 | ABM | 2 x 250 µl, 1 x 10^9 GC/ml, Titer: 1 x 10^9 GC/ml | EUR 375 |
Description: This AAV vector expresses the Cas9 orthologue from Staphylococcus Aureus (saCas9). saCas9 is ~1 kb shorter than spCas9, allowing it to be efficiently packaged in AAV Virus. Furthermore, the saCas9 enzyme recognizes a longer PAM sequence than spCas9, and thus has greater editing specificity.AAV has low immunogenicity and broad host range, making it an ideal choice for both in vivo and in vitro applications. Use this saCas9-expressing AAV virus with a target-specific saCas9-compatible sgRNA for highly specific and efficient genome editing. |
saCas9 Nuclease AAV Virus (AAV6) |
|||
K213 | ABM | 2 x 250 µl, 1 x 10^9 GC/ml, Titer: 1 x 10^9 GC/ml | EUR 375 |
Description: This AAV vector expresses the Cas9 orthologue from Staphylococcus Aureus (saCas9). saCas9 is ~1 kb shorter than spCas9, allowing it to be efficiently packaged in AAV Virus. Furthermore, the saCas9 enzyme recognizes a longer PAM sequence than spCas9, and thus has greater editing specificity.AAV has low immunogenicity and broad host range, making it an ideal choice for both in vivo and in vitro applications. Use this saCas9-expressing AAV virus with a target-specific saCas9-compatible sgRNA for highly specific and efficient genome editing. |
saCas9 Nuclease AAV Virus (AAV7) |
|||
K214 | ABM | 2 x 250 µl, 1 x 10^9 GC/ml, Titer: 1 x 10^9 GC/ml | EUR 375 |
Description: This AAV vector expresses the Cas9 orthologue from Staphylococcus Aureus (saCas9). saCas9 is ~1 kb shorter than spCas9, allowing it to be efficiently packaged in AAV Virus. Furthermore, the saCas9 enzyme recognizes a longer PAM sequence than spCas9, and thus has greater editing specificity.AAV has low immunogenicity and broad host range, making it an ideal choice for both in vivo and in vitro applications. Use this saCas9-expressing AAV virus with a target-specific saCas9-compatible sgRNA for highly specific and efficient genome editing. |
saCas9 Nuclease AAV Virus (AAV8) |
|||
K215 | ABM | 2 x 250 µl, 1 x 10^9 GC/ml, Titer: 1 x 10^9 GC/ml | EUR 375 |
Description: This AAV vector expresses the Cas9 orthologue from Staphylococcus Aureus (saCas9). saCas9 is ~1 kb shorter than spCas9, allowing it to be efficiently packaged in AAV Virus. Furthermore, the saCas9 enzyme recognizes a longer PAM sequence than spCas9, and thus has greater editing specificity.AAV has low immunogenicity and broad host range, making it an ideal choice for both in vivo and in vitro applications. Use this saCas9-expressing AAV virus with a target-specific saCas9-compatible sgRNA for highly specific and efficient genome editing. |
saCas9 Nuclease AAV Virus (AAV9) |
|||
K216 | ABM | 2 x 250 µl, 1 x 10^9 GC/ml, Titer: 1 x 10^9 GC/ml | EUR 375 |
Description: This AAV vector expresses the Cas9 orthologue from Staphylococcus Aureus (saCas9). saCas9 is ~1 kb shorter than spCas9, allowing it to be efficiently packaged in AAV Virus. Furthermore, the saCas9 enzyme recognizes a longer PAM sequence than spCas9, and thus has greater editing specificity.AAV has low immunogenicity and broad host range, making it an ideal choice for both in vivo and in vitro applications. Use this saCas9-expressing AAV virus with a target-specific saCas9-compatible sgRNA for highly specific and efficient genome editing. |
Bovine Viral Diarrhea Virus (BVDV1-3) Erns IgG negative control serum |
|||
RV-500200-01N | Alpha Diagnostics | 1 ml | EUR 196.8 |
Bovine Viral Diarrhea Virus (BVDV1-3) Erns IgG positive control serum |
|||
RV-500200-02P | Alpha Diagnostics | 1 ml | EUR 270 |
Peripheral blood T lymphocytosis in thymoma: an perception into the immunobiology
Function: Peripheral blood T lymphocytosis (PBTL) is a uncommon, but poorly understood manifestations of thymoma, which is postulated to be linked with autoimmune/paraneoplastic manifestations reminiscent of myasthenia gravis (MG), pure crimson cell aplasia (PRCA), and so on.; extra generally encountered on this neoplasm.
Technique: We intention to explain the flowcytometric immunophenotypic information of PBTL in a 43-year-old male; 6 months after profitable completion of chemoradiotherapy (CT/RT) for a big, invasive, and metastatic kind B1 thymoma; and current a complete assessment of all such instances reported over final 42 years (N = 21) (1977-2019).
End result: A bigger measurement of the tumors (≥ 10 cm), presence of native invasion and/or distant metastasis, and kind B (cortical or lymphocyte wealthy) histology have been extra prone to be related to PBTL.
Tumors related to MG/PRCA (N = 9/21) are inclined to have decrease PBTL in comparison with these with out such manifestations; and PBTL subsided following thymectomy with or with out CT/RT. Immunophenotypic evaluation of PB revealed a CD8 + > CD4 + mature (naïve) polyclonal T cells resembling late cortical thymocytes.
Conclusion: Thymic intratumoral microenvironment may affect prevalence PBTL that will have a pathophysiologic hyperlink to the improvement of autoimmune manifestations. Immunophenotypic traits of peripheral blood lymphoid cells needs to be the clue for correct characterization and to keep away from a misdiagnosis of a lymphoproliferative neoplasm.
Immunobiology and immunotherapy of HCC: highlight on innate and innate-like immune cells
Immune-based therapies reminiscent of immune checkpoint inhibitors have revolutionized the systemic remedy of assorted most cancers varieties. The therapeutic utility of monoclonal antibodies concentrating on inhibitory pathways reminiscent of programmed cell death-1(PD-1)/programmed cell dying ligand 1 (PD-L1) and CTLA-Four to cells of the adaptive immune system has not too long ago been proven to generate significant enchancment within the medical final result of hepatocellular carcinoma (HCC).
However, present immunotherapeutic approaches induce sturdy responses in solely a subset of HCC sufferers. Since immunologic mechanisms reminiscent of continual irritation because of continual viral hepatitis or alcoholic and nonalcoholic fatty liver illness play a vital position within the initiation, improvement, and development of HCC, it is very important perceive the underlying mechanisms shaping the distinctive tumor microenvironment of liver most cancers.
The liver is an immunologic organ with giant populations of innate and innate-like immune cells and is uncovered to bacterial, viral, and fungal antigens via the gut-liver axis. Right here, we summarize and spotlight the position of those cells in liver most cancers and suggest methods to therapeutically goal them.
We additionally focus on present immunotherapeutic methods in HCC and description latest advances in our understanding of how the therapeutic potential of those brokers is perhaps enhanced.
Immunobiology of Acquired Resistance to Ticks
Ticks are blood-sucking arthropods of nice significance within the medical and veterinary fields worldwide. They’re thought of second solely to mosquitos as vectors of pathogenic microorganisms that may trigger critical infectious issues, such as Lyme borreliosis and tick-borne encephalitis.
Laborious (Ixodid) ticks feed on host animals for a number of days and inject saliva along with pathogens to hosts throughout blood feeding. Some animal species can purchase resistance to blood-feeding by ticks after a single or repeated tick infestation, leading to decreased weights and numbers of engorged ticks or the dying of ticks in subsequent infestations. Importantly, this acquired tick resistance (ATR) can scale back the chance of pathogen transmission from pathogen-infected ticks to hosts.
That is the idea for the event of tick antigen-targeted vaccines to forestall tick infestation and tick-borne illnesses. Accumulation of basophils is detected within the tick re-infested pores and skin lesion of animals exhibiting ATR, and the ablation of basophils abolishes ATR in mice and guinea pigs, illustrating the important position for basophils within the expression of ATR.
On this assessment article, we offer a complete overview of latest advances in our understanding of the mobile and molecular mechanisms accountable for the event and manifestation of ATR, with a selected give attention to the position of basophils.
T-cell immunobiology and cytokine storm of COVID-19
2019 coronavirus illness (COVID-19) presents as a newly acknowledged pneumonia and will quickly progress into acute respiratory misery syndrome which has caused a world pandemic. Till now, no healing remedy has been strongly beneficial for COVID-19 aside from customized supportive care.
T cells and virus-specific T cells are important to guard in opposition to virus an infection, together with COVID-19. Delayed immune reconstitution (IR) and cytokine storm (CS) stay critical obstacles for the treatment of COVID-19.
Most COVID-19 sufferers, particularly amongst aged sufferers, had marked lymphopenia and elevated neutrophils, however T cell counts in extreme COVID-19 sufferers surviving the illness progressively restored later.
Elevated pro-inflammatory cytokines, significantly IL-6, IL-10, IL-2, and IL-17, and exhausted T cells are present in peripheral blood and the lungs. It means that Thymosin α1 and adoptive COVID-19-specific T cells may enhance IR whereas convalescent plasma, IL-6 blockade, mesenchymal stem cells, and corticosteroids may suppress CS.
Extra medical research on this area worldwide are urgently warranted to pave the way in which for remedy of COVID-19 sooner or later.